Skip to main content
Premium Trial:

Request an Annual Quote

Singulex Secures Phase II SBIR from NCI to Develop Efficacy Assays for Cancer Drugs

NEW YORK (GenomeWeb) - Singulex said today that it has secured a Phase II Fast Track Small Business Innovation Research contract from the National Cancer Institute to develop biomarker assays to determine the effectiveness of potential cancer therapeutics.
The agreement extends a contract with NCI that Singulex originally signed in November 2007.
In Phase I of the SBIR, the company developed an assay to detect the VEGF protein, which is implicated in many cancers. The company said that its VEGF assay “overcomes the limitations of traditional biomarker detection technologies and allows drug developers to see normal levels of VEGF in blood and assess the efficacy of anti-VEGF drugs.”
In Phase II of the contract, the company said it plans to develop 12 more assays for different biomarkers “that will provide insights into drug efficacy in additional oncology areas."
The oncology assays developed with the NCI SBIR funds will be available to the company’s collaborators, which include Washington University and Sigma Aldrich.
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.